ABVC BioPharma (NASDAQ:ABVC) Stock Price Up 0.9% – What’s Next?

ABVC BioPharma, Inc. (NASDAQ:ABVC) shares traded up 0.9% during trading on Friday . The company traded as high as $1.10 and last traded at $1.09. 68,611 shares changed hands during trading, a decline of 7% from the average session volume of 73,972 shares. The stock had previously closed at $1.08.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut ABVC BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

ABVC BioPharma Price Performance

The stock has a 50-day moving average price of $1.20 and a 200 day moving average price of $1.86. The firm has a market cap of $27.73 million, a price-to-earnings ratio of -2.73 and a beta of 0.42.

ABVC BioPharma (NASDAQ:ABVC) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.11) EPS for the quarter.

Hedge Funds Weigh In On ABVC BioPharma

Several institutional investors have recently added to or reduced their stakes in ABVC. Geode Capital Management LLC increased its position in ABVC BioPharma by 5.8% in the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after acquiring an additional 6,017 shares during the period. Citadel Advisors LLC acquired a new position in ABVC BioPharma in the 3rd quarter valued at about $48,000. Finally, Millennium Management LLC acquired a new position in ABVC BioPharma in the 3rd quarter valued at about $60,000. Institutional investors and hedge funds own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.